MannKind completes Phase III recruitment for inhaled insulin; Genetic variants increase Parkinson's risk;

> MannKind has completed recruitment for two Phase III studies of Afrezza, its inhaled human insulin for mealtime use, using the company's next-generation inhaler. Article

> Genetic variants appear to increase the risk of developing Parkinson's disease, and may point the way to new treatments. Press release | Paper

> Alimera Sciences has closed a $40 million round of funding. Press release | Article

> Hydrogel releases protein drugs deep into tissues when hit with light. Article

> Once-weekly transdermal buprenorphine delivers steady levels of drugs. Abstract

And Finally… The agreement between Revance Therapeutics and Medicis Pharmaceutical has been terminated and Revance has regained all worldwide development and commercialization rights to its wrinkle treatments--RT001 botulinum toxin type A topical gel for crow's feet, along with its RT002 injectable botulinum toxin type A for longer-term wrinkle treatment. This will resolve the outstanding litigation between the companies. Press release | Article

Suggested Articles

The new digital Abilify is a breakthrough for Proteus Digital Health and its patient-tracking products, but not so much for Abilify's maker, Otsuka.

Adamis Pharmaceuticals' EpiPen contender Symjepi, which was rejected last year before the EpiPen havoc, won approval from the FDA.

Researchers in the U.K. have developed a technique to better predict results in liver cancer when drug-laden polymer beads are used to deliver medicines.